Dedicated to Research Since 1993
  •  

    info@genesismarketinsights.com

Diabetes Drugs Market By Products & Services (Insulin Derivatives, Rapid-acting insulin, Intermediate-acting insulin, Long-acting insulin) By Application (Type 1 Diabetes, Type 2 Diabetes) - Global outlook Analysis and Industry Forecast, 2017-2022.

 Healthcare and Pharmaceuticals

Report Overview

GLOBAL DIABETES DRUG MARKET was valued at USD 47.2 Billion in the year 2017. Global Diabetes Drug Market is further estimated to grow at a CAGR of 7.09% from 2018 to reach USD 70.9 Billion by the year 2023. North America region holds the highest market share in 2017 and Asia-Pacific is considered as the fastest growing market in the forecasted period. At a country level, developed markets the U.S. holds a substantial market share in 2017 and it is projected to grow at a gradual pace in the coming years.

Abbott Laboratories (U.S.), Novartis AG (Switzerland), Novo Nordisk (Denmark), Bayer Healthcare AG (Germany) , Johnson & Johnson (U.S) and Sanofi (France) are some of the key players in the Diabetes Drug Market with Novo Nordisk (Denmark) holding the significant market share because of its better global presence both at production and at an operational level. Rising research and development expenses to address the changing demand of end users. Similarly, growth strategies such as acquisition, merger, and expansion of the distribution network were few techniques adopted by most of the top players in the last 5 years.

Drivers:

            Improved diagnosis and advances in treatment

            Increasing diabetic population

Restraints:

            Lack of awareness among people

            Increased Risk of Cardiovascular Complications

Opportunities:

            Launching of advance and new Anti-Diabetes Drugs

            High growth opportunity in the Emerging Market

Challenges:

            Other emerging therapy markets

            Patent Expiries and Rising Competition of Generic Drugs

The global diabetes drug market id segmented on the basis of products & services, by application and by region. On the basis of products and services, the Insulin Derivative segment is expected to hold the highest market share during the forecast period. Due to its high price, rising geriatric population and need & demand for insulin.

On the basis of application, the market is segmented as type 1 and type 2 diabetes, in which type 2 diabetes holds the highest market share owing to the 90% of diabetic patients suffering from type 2 diabetes.

Key Benefits for Stakeholders

Diabetes Drug Manufacturers and biotechnological institute

Blood banks, private hospitals and institutes

Research and Consulting organization.

Medical research laboratories

By Products & Services

Insulin Derivatives

            Rapid-acting insulin

            Intermediate-acting insulin

            Long-acting insulin

Oral Diabetic Medication Drugs

            Sulfonylurea

            Metformin

            Alpha-Glucosidase inhibitor

            Thiazolidinediones

            Biguanide

            Meglitinides

            GPP4-Inhibitors

            GLP-1

By Application

Type 1 Diabetes

Type 2 Diabetes

By Region

North America

Europe

Asia-Pacific

RoW

Key Market Players

Abbott Laboratories       

AstraZeneca PLC           

Bayer Healthcare AG     

Dexcom Inc.     

GlaxoSmithKline PLC     

Johnson & Johnson        

Sanofi  

Merck & Co.      

Novartis AG      

Novo Nordisk

(Another brief information of 10 companies will be provided in the report.)

Research Methodology:

Genesis Market Insights follows in-depth Research Methodology focused on reducing deviation in the collected data. GMI offers the most precise evaluations and projection for the market numbers. GMI engages following Market Engineering techniques –

  1. Raw Market Data is collected and compared with the Existing in-house Data on a broad front.
  2. Both Bottom-Up and Top-Down approaches are analyzed for segmenting and estimating measurable aspects of the market.
  3. To avoid bias, we filter the collected data collected from authenticated sources.
  4. GMI has a well proven Statistical Modeling System for estimates and forecasts.
  5. Further, the report findings are validated with the Industry Expert Panel on face to face or telephonic interviews.
  6. Panelists are approached from Leading Enterprises across the value chain including manufacturers, suppliers, technology providers, domain experts and buyers so as to validate a thorough and balanced market overview.

Detailed customization is also available for you. Further, if the report listed above does not meet with your key requirements. Our customized research report will analytically cover the required market information you need which will help you to plan your business decisions.

Table Of Content

1. Introduction

1.1 Market Vision

       1.1.1 Market Definition

       1.1.2 Market Scope

1.2 Limitations

1.3 Stakeholders

2. Research Methodology

2.1. Research Process

       2.1.1. Secondary Research

             2.1.1.1. Key Data from Secondary Research

       2.1.2. Primary Research

             2.1.2.1. Key Data from Primary Research

             2.1.2.2. Breakdowns of Primary Interviews

2.2. Market Size Estimation

       2.2.1. Bottoms-Up Approach

       2.2.2. Top-Down Approach

       2.2.3. Annual Revenue Process

2.3. Data Triangulation 

2.4. Research Assumptions 

       2.4.1. Assumption

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Drivers

4.3. Restraints

4.4. Opportunities

4.5. Challenges

4.6. Regulations

4.7. Supply Chain/Value Chain Analysis

4.8. Patent & Standards

5. Industry Trends

5.1. Introduction

5.2. Porter’s Five Forces Analysis

       5.2.1. Threat of New Entrants

       5.2.2. Threat of Substitutes

       5.2.3. Bargaining Power of Buyers

       5.2.4. Bargaining Power of Suppliers

       5.2.5. Intensity of Competitive Rivalry

6. Diabetes Drug Market, By Products & Services

6.1. Insulin Derivatives

            6.1.1 Rapid-acting insulin

            6.1.2 Intermediate-acting insulin

            6.1.3 Long-acting insulin

6.2. Oral Diabetic Medication Drugs

6.2.1 Sulfonylurea

6.2.2 Metformin

6.2.3 Alpha-Glucosidase inhibitor

6.2.4 Thiazolidinediones

6.2.5 Biguanide

6.2.6 Meglitinides

6.2.7 GPP4-Inhibitors

6.3 GLP-1

7. Diabetes Drug Market, By Application

7.1. Type 1 Diabetes

7.2. Type 2 Diabetes

8. Geographical Analysis

8.1. Introduction

8.2. North America

       8.2.1. U.S.

       8.2.2. Canada

       8.2.3. Mexico

8.3. Europe

       8.3.1. U.K.

       8.3.2. Germany

       8.3.3. Italy

       8.3.4. France

       8.3.5. RoE

8.4. Asia Pacific

       8.4.1. South Korea

       8.4.2. China

       8.4.3. Japan

       8.4.4. South Korea

       8.4.5. RoAPAC

8.5. RoW

       8.5.1. Latin America

       8.5.2. Middle East and Africa

9. Company Profiles

(Business Overview, Financial Overview, Product write Up, Recent Developments)

9.1. Abbott Laboratories 

9.2 AstraZeneca PLC     

9.3 Bayer Healthcare AG

9.4 Dexcom Inc.

9.5 GlaxoSmithKline PLC

9.6 Johnson & Johnson   

9.7 Sanofi         

9.8 Merck & Co.

9.9 Novartis AG 

9.10 Novo Nordisk 

(Another brief information of 10 companies will be provided in the report.)

10. Competitive Analysis

10.1. Introduction

10.2. Market Positioning of Key Players

10.3 Competitive Strategies Adopted by Leading Players

        10.3.1. Investments & Expansions

        10.3.2. New Product Launches

        10.3.3. Mergers & Acquisitions

        10.3.4. Agreements, Joint Ventures, and Partnerships

11. Appendix

11.1. Questionnaire

11.2. Available Customizations 

11.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

Summary

No Content Available.